Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Receives $37.11 Average PT from Analysts

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) has been assigned a consensus rating of “Moderate Buy” from the eleven analysts that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, nine have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $37.5556.

A number of brokerages have recently issued reports on TEVA. Truist Financial boosted their target price on shares of Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the company a “buy” rating in a research report on Wednesday, February 18th. Piper Sandler boosted their price objective on shares of Teva Pharmaceutical Industries from $30.00 to $40.00 and gave the company an “overweight” rating in a report on Monday, December 22nd. JPMorgan Chase & Co. increased their target price on shares of Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 16th. The Goldman Sachs Group lifted their price target on shares of Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the company a “buy” rating in a research report on Monday, February 9th. Finally, Scotiabank boosted their price target on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company a “sector outperform” rating in a research note on Thursday, January 29th.

Insider Buying and Selling

In related news, insider Mark Sabag sold 216,892 shares of the company’s stock in a transaction dated Tuesday, December 9th. The shares were sold at an average price of $28.73, for a total transaction of $6,231,307.16. Following the completion of the sale, the insider owned 52,828 shares of the company’s stock, valued at $1,517,748.44. This represents a 80.41% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP Richard Daniell sold 115,468 shares of the stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $28.68, for a total transaction of $3,311,622.24. Following the sale, the vice president owned 48,384 shares in the company, valued at $1,387,653.12. The trade was a 70.47% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 422,060 shares of company stock valued at $12,254,965. 0.49% of the stock is owned by insiders.

Institutional Trading of Teva Pharmaceutical Industries

A number of institutional investors and hedge funds have recently made changes to their positions in TEVA. Dorsey Wright & Associates bought a new position in Teva Pharmaceutical Industries in the fourth quarter valued at approximately $1,640,000. Compound Planning Inc. bought a new stake in Teva Pharmaceutical Industries during the fourth quarter worth $323,000. Invesco Ltd. boosted its holdings in shares of Teva Pharmaceutical Industries by 4.8% in the 4th quarter. Invesco Ltd. now owns 2,710,105 shares of the company’s stock valued at $84,582,000 after purchasing an additional 124,304 shares in the last quarter. Corient Private Wealth LLC increased its stake in shares of Teva Pharmaceutical Industries by 30.4% in the 4th quarter. Corient Private Wealth LLC now owns 49,848 shares of the company’s stock valued at $1,520,000 after purchasing an additional 11,628 shares during the last quarter. Finally, Alpine Woods Capital Investors LLC bought a new position in shares of Teva Pharmaceutical Industries in the 4th quarter valued at $463,000. Institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Trading Down 0.9%

Shares of NYSE:TEVA opened at $33.91 on Tuesday. Teva Pharmaceutical Industries has a 12-month low of $12.47 and a 12-month high of $37.35. The business has a 50 day moving average of $32.65 and a 200-day moving average of $25.32. The company has a quick ratio of 0.80, a current ratio of 1.04 and a debt-to-equity ratio of 1.89. The stock has a market cap of $38.99 billion, a PE ratio of 28.26, a P/E/G ratio of 11.45 and a beta of 0.70.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Wednesday, January 28th. The company reported $0.96 earnings per share for the quarter, topping the consensus estimate of $0.65 by $0.31. The business had revenue of $4.71 billion during the quarter, compared to analysts’ expectations of $4.36 billion. Teva Pharmaceutical Industries had a return on equity of 46.28% and a net margin of 8.16%.The firm’s revenue for the quarter was up 11.4% compared to the same quarter last year. During the same period last year, the firm posted $0.71 EPS. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. As a group, equities research analysts forecast that Teva Pharmaceutical Industries will post 2.5 earnings per share for the current year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.